by Mark Barnes | Jan 22, 2025 | Press Release
In line with our transition from a CRO to a biotechnology company, Liverpool ChiroChem Ltd has officially been renamed to ‘LCC Therapeutics Ltd’. LCC Therapeutics is developing best-in-class small molecule therapeutics. We have built and validated our platform over 10...
by Mark Barnes | Dec 23, 2024 | Press Release
Liverpool ChiroChem Ltd. (hereinafter referred to as “LCC”) and Veritas In Silico Inc. (hereinafter referred to as “VIS”) announce that LCC and VIS have entered into a Collaboration Development & Commercialisation Agreement today to jointly generate mRNA-targeted...
by Mark Barnes | Dec 10, 2024 | Press Release
LCC is transitioning from a CRO to a hub-and-spoke biotech company, generating small molecule lead candidate assets against oncology and rare disease targets. LCC built and validated its chemistry platform over 10 years via successful delivery across multiple target...
by Mackenzie | Nov 11, 2024 | Press Release
Liverpool ChiroChem and Veritas In Silico Agree to Form a Strategic Partnership of mRNA-Targeted Drug Discovery and Development Photographed at the VIS office in Gotanda, Tokyo: Dr Paul Colbon, CEO & Founder of LCC on the left, and Dr Shingo Nakamura,...
by Mackenzie | Oct 31, 2024 | News, Press Release
LCC has announced that Dr Steven Powell has been appointed to the Board of the Company as a Non-Executive Chair. Steven is a dedicated life-science professional with a proven track record; he has supported several companies’ developments and exits over an...
by Mackenzie | Aug 14, 2024 | News, Press Release
LCC has announced that Dr Gary Tilbrook has been appointed to the Board of the Company as a Chief Scientific Officer. Gary is an experienced medicinal chemist with an in-depth knowledge of drug discovery and development, built from working within the biotech sector...